Master PathAI with our step-by-step tutorial, detailed feature walkthrough, and expert tips.
Explore the key features that make PathAI powerful for ai healthcare workflows.
Cloud-native enterprise workflow system that centralizes case management, whole-slide image management, and AI diagnostic applications in a single hub for anatomic pathology laboratories.
Large hospital pathology departments replacing manual slide workflows with digital-first operations, enabling remote consultation and AI-assisted primary diagnosis.
510(k)-cleared platform for AI-powered primary diagnosis with a Predetermined Change Control Plan allowing iterative AI improvements without new FDA submissions.
Clinical laboratories deploying AI-assisted cancer detection and grading for breast, lung, and GI cancers with full regulatory compliance for diagnostic use.
Standardized, reproducible AI-powered biomarker analysis across tissue samples for pharmaceutical clinical trials, reducing inter-reader variability in pathology scoring.
Pharma companies running oncology clinical trials that need consistent PD-L1 scoring, HER2 quantification, or tumor-infiltrating lymphocyte analysis across multiple trial sites.
Global network of digital pathology laboratories launched in 2025 that provides early access to AI tools, enables real-world data monetization, and supports biopharma evidence generation studies.
Regional pathology labs joining a collaborative network to access cutting-edge AI algorithms while generating revenue from anonymized pathology data contributions.
CAP/CLIA-certified laboratory operated by PathAI that provides end-to-end tissue processing, staining, scanning, and AI analysis for clinical trial sponsors.
Biopharma companies outsourcing entire pathology workflows for Phase II/III clinical trials to a single vendor with integrated AI-powered analysis.
Yes. PathAI received FDA 510(k) clearance for AISight Dx for primary diagnosis, and in 2025 obtained clearance with a Predetermined Change Control Plan (PCCP) that allows specific AI enhancements without new regulatory submissions.
PathAI uses enterprise pricing with per-site licenses or usage-based models tied to slide volumes and specific AI applications. Biopharma projects are structured as separate service engagements. It is not positioned as a tool for small private labs.
PathAI's algorithms cover multiple tumor types including breast, lung, head and neck, and gastrointestinal cancers, with specific applications for tumor detection, grading, and biomarker quantification like PD-L1 and HER2.
Yes. AISight is designed to integrate with existing LIS and LIMS workflows, serving as a centralized hub that connects case management, image management, and AI applications within existing laboratory infrastructure.
Now that you know how to use PathAI, it's time to put this knowledge into practice.
Sign up and follow the tutorial steps
Check pros, cons, and user feedback
See how it stacks against alternatives
Follow our tutorial and master this powerful ai healthcare tool in minutes.
Tutorial updated March 2026